Zobrazeno 1 - 10
of 47
pro vyhledávání: ''
Autor:
John D. Hainsworth, John D. Zubkus, Mythili Shastry, Patrick J. Ward, L Finney, Denise A. Yardley, Aruna Mani, Dianna Shipley, Gail Lynn Shaw Wright, Laura M. DeBusk
Publikováno v:
Clinical Breast Cancer. 19:1-9
Background Eribulin mesylate is a non–taxane microtubule inhibitor effective in the treatment of metastatic breast cancer refractory to anthracyclines and taxanes. In preclinical studies, additional mechanisms of eribulin included reversal of epith
Autor:
Hiroaki Toba, Kazumasa Okumura, Akira Tangoku, Naoki Hino, Mayumi Ikeuchi, Takahiro Yoshida, Hirokazu Takechi, Masami Morimoto, Aya Nishisho, Misako Nakagawa
Publikováno v:
Clinical Breast Cancer. 19:10-16
Background To improve the pathological complete response (pCR) rate, we devised new neoadjuvant chemotherapy. Efficacy and safety of the oral fluoropyrimidine derivative S-1 (Taiho Pharmaceutical Co, Tokyo, Japan) combined with low-dose docetaxel (S-
Autor:
Rahul Ladwa, Shivanshan Pathmanathan, Jasotha Sanmugarajah, Natasha Woodward, David Wyld, Timothy Kalas
Publikováno v:
Clinical Breast Cancer. 18:e1181-e1187
Maintaining the relative dose intensity (RDI) of adjuvant chemotherapy at ≥ 85% has been associated with improved treatment outcomes in early-stage breast cancer (ESBC). Increasing evidence has suggested that patients aged ≥ 65 years can maintain
Autor:
Robert W. Mutter, Sarah S. Mougalian, Heather B. Neuman, Charles L. Loprinzi, Rachel A. Freedman, Alexis D. Leal, Tufia C. Haddad, Ahmedin Jemal, Lindsey R. Sangaralingham, Kathryn J. Ruddy, Holly K. Van Houten, Cary P. Gross, Nilay Shah, Theresa H.M. Keegan
Publikováno v:
Clinical breast cancer, vol 18, iss 4
BackgroundTreatment-related toxicity can vary substantially between chemotherapy regimens. In this study we evaluated the frequency of outpatient office visits among a cohort of early stage breast cancer survivors after completion of 4 different adju
Autor:
Y Liu, Raymond C. Bergan, Yueping Liu, Xiangmei Zhang, Zhenzhen Zhang, Motomi (Tomi) Mori, Miao Cao, Shiuh Wen Luoh, Beichen Liu
Publikováno v:
Clinical breast cancer. 20(4)
Background To explore the potential advantage of preoperative anti-angiogenosis therapy, we implemented a study to evaluate the efficacy of recombinant human endostatin (EN) in combination with neoadjuvant chemotherapy in the treatment of stage III b
Autor:
Eunyoung Kang, Jeong Eon Lee, Seok Won Kim, Soo Youn Bae, Jai Min Ryu, Se Kyung Lee, Sungmin Park, Eun Joo Yang, Seok Jin Nam, Jonghan Yu, Hyun June Paik, Eun Kyu Kim, Isaac Kim
Publikováno v:
Clinical Breast Cancer. 18:e49-e54
Introduction The aim of our study was to analyze the risk of lymphedema (LE) according to the clinicopathologic factors and to investigate the serial change in body weight during neoadjuvant anthracycline plus cyclophosphamide followed by taxane and
Autor:
Margi Patel, Karen Fehn, Eleni Andreopoulou, John J. Wright, Christine M. Pellegrino, Joseph A. Sparano, Jesus Anampa, Alice P. Chen
Publikováno v:
Clinical Breast Cancer. 18:e135-e142
Background Poly-ADP-ribose-polymerase is an essential nuclear enzyme, involved in base-excision repair of damaged DNA. Poly-ADP-ribose-polymerase inhibition sensitizes tumor cells to cytotoxic agents, which induce DNA damage, including cyclophosphami
Autor:
Rabab Gaafar, Marwa M. Hussein, Wafaa A. Ahmed, Salem E. Salem, Ibrahem Mohamed Abdel-Salam, Nasr Allahloubi, Ahmed Mostafa Abdel-Warith
Publikováno v:
Clinical Breast Cancer. 17:618-628
Metronomic chemotherapy (MC) has shown efficacy in patients with metastatic breast cancer (MBC). We therefore tested the efficacy and toxicity of MC in pretreated MBC.This prospective phase II study included 50 patients with heavily pretreated MBC wh
Autor:
Andreas Schneeweiss, Bernadette Jaeger, Marianna Alunni-Fabbroni, Sven Mahner, Brigitte Rack, Nikolaus de Gregorio, Elisabeth Trapp, Angelika Ober, A Schramm, Klaus Pantel, Thomas Decker, Wolfgang Janni, Peter A. Fasching, Thomas W. P. Friedl, Georg Heinrich, Oumar Camara, Fabienne Schochter, Ulrich Andergassen, Tanja Fehm
Publikováno v:
Clinical Breast Cancer. 17:279-285
Background Use of anthracycline-based chemotherapy in patients with early breast cancer (EBC) has been well-established but is often associated with cardiotoxicity. Based on data suggesting a limited benefit of anthracyclines in human epidermal growt
Autor:
Wolfgang Janni, Nadia Harbeck, Brigitte Rack, Marion Kiechle, Lukas Schwentner, Elena Leinert, Tobias Weissenbacher, Visnja Fink, A Wischnik, Martin Eichler, Doris Augustin, Susanne Singer, Johannes Ettl
Publikováno v:
Clinical Breast Cancer. 17:100-106
Elderly breast cancer patients are affected by poorer quality of life (QoL) compared to younger patients. Because QoL has a relevant impact on guideline-adherent treatment, elderly breast cancer patients are often undertreated, especially with regard